Pfizer La Jolla
Pfizer La Jolla's 1,000 scientists and staff focus on discovering and developing new medicines to treat many forms of cancer and diseases of the eye (e.g. glaucoma and macular degeneration). For additional information, see Research Highlights below.
Pfizer invested more than $522 million in creating a fully integrated R&D campus in La Jolla. The 33.5-acre campus includes eight buildings, totaling more than 1-million square feet. Pfizer scientists pursue new medicines from concept to regulatory approval in state-of-the-art facilities with specialized laboratories and equipment for structural and computational biology, molecular design, high throughput chemistry and pharmacology.
Pfizer is an important part of California's life sciences community and partners with academic institutions and other research organizations to advance scientific understanding and deliver new medicines. In 2007, Pfizer launched a new 28,000-square-foot incubator facility (The Pfizer Incubator) on the La Jolla campus with eight high-tech chemistry and biology labs as well as adjoining office space. Pfizer will invest $10 million a year in The Pfizer Incubator, supporting life science start-ups that are working on projects related to the company's prime therapeutic areas. In addition, Pfizer is investing $100 million over five years in a research collaboration with The Scripps Research Institute to advance scientific knowledge of today's incurable diseases and novel ways to treat them.
The Pfizer La Jolla campus is on a mesa less than one mile from the Pacific Ocean. Within a 10-mile radius are major educational and research facilities, such as the University of California at San Diego, The Scripps Research Institute, the Salk Institute for Biological Studies and some 200 biotech firms.
La Jolla Laboratories is the center of Pfizer's research and development in oncology. Researchers are working to find treatments that focus on specific targets important in tumor growth and survival. In early 2006, the FDA approved Sutent®, a drug developed at Pfizer La Jolla for treating intestinal and kidney cancers. Its novel mechanism both cuts off the blood supply to the cancer and destroys cellular reproduction. Pfizer La Jolla colleagues are currently involved in teams that are progressing equally innovative compounds through clinical trials on breast, liver, thyroid, lung and colorectal cancers.
La Jolla Laboratories is also home to Pfizer's research and development in ophthalmology. Researchers are currently focused on a number of targets, including glaucoma and macular degeneration. Glaucoma is the leading cause of blindness in the United States today with more than 2 million patients suffering from the most common form – open angle glaucoma. Pfizer's Xalatan® is the leading treatment for the debilitating disease and researchers are continuing to seek new treatments. In 2004, the FDA approved Macugen® (pegaptanib), the first drug in its class for the treatment of wet age-related macular degeneration. Pfizer La Jolla is advancing other compounds for possible treatment of macular degeneration.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.